Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’
June 22, 2020
Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals’ cystic fibrosis drug is not “discrimination.”
Kreis, whose 18-year-old daughter has cystic fibrosis, was referring to how some critics responded to ICER’s suggestion that the drug, Trikafta, was too expensive at $312,000.
“The idea that it is discrimination to hold Vertex accountable for the obscene price of Trikafta has to do with a key metric employed by ICER in its analysis,” he writes in a piece published on the Morning Consult. “At issue is the Quality-Adjusted Life Year.”
To read the full article, click here.
